

Published papers involving the use of the CDR System

Age Associated Memory Impairment & Mild Cognitive Impairment (MCI)

Dunbar GC, Kuchibhatla R, Lee G (2011). A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment. *Journal of Psychopharmacology*. 25: 1020-1029.

Dunbar GC, Inglis F, Kuchibhatla R, Sharma T, Tomlinson M, Wamsley J (2006). Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). *Journal of Psychopharmacology*. 21: 171-178.

Fard MT, Cribb L, Nolidin K, Savage K, Wesnes KA, Stough C (2020) Is there a relationship between low-grade systemic inflammation and cognition in healthy people aged 60–75 years? *Behavioural Brain Research*. 383: 112502

Harrison SL, de Craen AJ, Kerse N, Teh R, Granic A, Davies K, Wesnes KA, den Elzen WP, Gussekloo J, Kirkwood TB, Robinson L, Jagger C, Siervo M, Stephan BC (2017). Predicting Risk of Cognitive Decline in Very Old Adults Using Three Models: The Framingham Stroke Risk Profile; the Cardiovascular Risk Factors, Aging, and Dementia Model; and Oxi-Inflammatory Biomarkers. *J Am Geriatr Soc*. 65(2): 381-389. doi: 10.1111/jgs.14532.

Mendonça N, Granic A, Mathers JC, Martin-Ruiz C, Wesnes KA, Seal CJ, Jagger C, Hill TR (2017). One-Carbon Metabolism Biomarkers and Cognitive Decline in the Very Old: The Newcastle 85+ Study. *J Am Med Dir Assoc*. 18(9): 806.e19-806.e27. doi: 10.1016/j.jamda.2017.05.008.

Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED (2012). Nicotine Treatment of Mild Cognitive Impairment: A Six-Month Double-Blind Pilot Clinical Trial. *Neurology* 84: 91-101.

Nicholl CG, Lynch S, Kelly CA, White L, Simpson PM, Wesnes KA, Pitt BMN (1995). The Cognitive Drug Research computerised assessment system in the evaluation of early dementia - is speed of the essence? *International Journal of Geriatric Psychiatry*. 10: 199-206.

Wesnes KA (2000). Predicting, assessing, differentiating and treating the dementias: experience in MCI and various dementias using the CDR computerised cognitive assessment system. In: B. Vellas & LJ Fitten (Eds) *Research and practice in Alzheimer's disease*, Volume 3. Serdi, Paris, 59-65.

Wesnes KA, Simmons D, Rook M, Simpson PM (1987). A double blind placebo controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly. *Human Psychopharmacology*. 2: 159-169.

Wesnes KA, Ward T. (2002) *Treatment of Age-Associated Memory Impairment*. In: N Qizilbash, LS Schneider, H Brodaty, P Tariot, J Kaye, H Chui, T Erkinjuntti, ZS (Eds.). *Evidence based Dementia Practice*. Wiley- Blackwell, ISBN: 978-0-632-05296-7, pp 639-653.

Ageing Registries

Bucks RS, Dunlop PD, Taljaard DS, Brennan-Jones CG, Hunter M, Wesnes K, Eikelboom RH (2016). The association between hearing loss and cognition in the Busselton Baby Boomer cohort: an epidemiological study of adults born 1946 to 1964. *The Laryngoscope*. 126 (10): 2367-2375 doi.org/10.1002/lary.25896

Collerton J, Barrass K, Bond J, Eccles M, Jagger C, James O, Martin-Ruiz C, Robinson L, von Zglinicki T, Kirkwood T. (2007). The Newcastle 85+ study: biological, clinical and psychosocial factors associated with healthy ageing: study protocol. *BMC Geriatrics* 7:14 doi:10.1186/1471-2318-7-14. 288.

Collerton J, Collerton D, Yasumichi A, Barrass K, Eccles M, Jagger C, McKeith IG, Saxby BK, Kirkwood T (2007). A comparison of computerized and pencil-and-paper tasks in assessing cognitive function in community dwelling older people in the Newcastle 85+ pilot study. *Journal of the American Geriatrics Society*. 55: 1630-1635.

Granic A, Hill T, Kirkwood T, Davies K, Collerton J, Martin-Ruiz C, von Zglinicki T, Saxby B, Wesnes KA, Collerton D, McKeith I, Mathers JC, Jagger C. (2014). Serum 25(OH)D and cognitive decline in the very old: The Newcastle 85+ Study. *European Journal of Neurology* 22: 106-115.

Harrison SL, Stephan BCM, Siervo M, Granic A, Davies A, Wesnes KA, Kirkwood TBL, Robinson L, Jagger C (2015). Is there an association between metabolic syndrome and cognitive function in the very old? The Newcastle 85+ study. *Journal of the American Geriatrics Society* DOI: 10.1111/jgs.13358

Parkinson's disease

Aarsland D, Bronnick K, Williams-Gray C et al (2010) Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. *Neurology* 75: 1062-1069.

Allcock L M, Kenny R A, Mosimann U P, Tordoff S, Wesnes K A, Hildreth A J and Burn D J (2006). Orthostatic hypotension in Parkinson's disease: association with cognitive decline? *International Journal of Geriatric Psychiatry*. 21: 778-783.

Allcock L M, Rowan E N, Steen I N, Wesnes K A, Kenny R A and Burn D J (2009). Impaired attention predicts falling in Parkinson's disease. *Parkinsonism and Related Disorders*. 15: 110-115.

Almeida OP, Burton EJ, McKeith I, Gholkar A, Burn D, O'Brien JT (2003). MRI Study of Caudate Nucleus Volume in Parkinson's Disease with and without Dementia with Lewy Bodies and Alzheimer's Disease. *Dementia and Geriatric Cognitive Disorders*. 16: 57-63.

Carbutt S, Duff J, Yarnall A, Burn DJ, Hudson G. (2015) Variation in complement protein C1q is not a major contributor to cognitive impairment in Parkinson's disease. *Neurosci Lett*. 594:66-9. doi: 10.1016/j.neulet.2015.03.048.

Dissanayaka NNW, Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Barker RA, Burn DJ; ICICLE-PD study group (2017). Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease. *Parkinsonism Relat Disord*. 36: 63-68. doi: 10.1016/j.parkreldis.2017.01.001.

bank MJ, Yarnall AJ, Lawson RA, Duncan GW, Khoo TK, Petrides GS, O'Brien JT, Barker RA, Maxwell RJ, Brooks DJ, Burn DJ (2016). Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study. *J Neurol Neurosurg Psychiatry*. 88(4): 310-316. doi: 10.1136/jnnp-2016-313918.

Hudson G, Stutt A, Eccles M, Robinson L, Allcock LM, Wesnes KA, Chinnery PF, Burn DJ (2010). Genetic variation of CHRNA4 does not modulate attention in Parkinson's Disease. *Neuroscience Letters* 479: 123-125.

Litvan I, Aarsland D, Mayeux R et al (2011) MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI. *Movement Disorders* 26: 1814–1824.

Mace J, Porter R, Dalrymple-Alford J, Wesnes KA, Anderson T (2009). Effects of acute tryptophan depletion on neuropsychological and motor function in Parkinson's disease. *Journal of Psychopharmacology* doi:10.1177/0269881109105721.

Molloy S, Rowan EN, O'Brien JT, McKeith IG, Wesnes KA, Burn DJ (2006). The effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. *Journal of Neurology Neurosurgery & Psychiatry*. 77: 1323-1328.

Moon GA, Wesnes KA, Manktelow TC (2002). Cognitive Deficits in Recently Diagnosed Untreated Patients with Parkinson's Disease. Poster Presented at British Association for Psychopharmacology Annual Meeting, 2002.

Mosimann UP, Mather G, Wesnes KA, O'Brien JT, Burn DJ, McKeith IG (2004). Visual perception in Parkinson disease dementia and dementia with Lewy bodies. *Neurology*. 63: 2091-2096.

Swartz J, Wesnes KA, Burn D (2012). The Frequency of Mild Cognitive Impairment in Parkinson's Disease as Assessed with Automated Cognitive Tests. Presented at the 8th International Congress On Mental Dysfunction & Other Non-Motor Features In Parkinson's Disease and Related Disorders (MDPD), Berlin, Germany May 3-6 2012

Taylor JP, Rowan EN, Lett D, O'Brien JT, McKeith IG, Burn D (2008). Poor attentional function predicts cognitive decline in non-demented Parkinson's disease patients independent of motor phenotype. *Journal of Neurology, Neurosurgery, and Psychiatry*. 79: 1318-1323.

Thevathasan W, Silburn PA, Brooker H, Coyne TJ, Khan S, Gill SS, Aziz TZ, Brown P (2010). The impact of low frequency stimulation of the pedunculo-pontine nucleus region on reaction time in Parkinsonism. *J Neurol Neurosurg Psychiatry* 2010;81: 1099-1104 doi:10.1136/jnnp.2009.189324

Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ, Nombela-Otero C, Rowe J, Mollenhauer B, Hudson G, Chinnery PF, O'Brien JT, Robbins TW, Wesnes KA, Brooks DJ, Barker RA, Burn JA (2014). Characterising Mild Cognitive Impairment in Incident Parkinson's Disease: The ICICLE-PD Study. *Neurology* 82: 308-316.

Wesnes KA, Burn DJ. (2013). Compromised object pattern separation performance in Parkinson's disease suggests dentate gyrus neurogenesis may be compromised in the condition. *Journal of Alzheimer's Disease & Parkinsonism* 3: 131. doi: 10.4172/2161-0460.1000131

Delirium & Post-Operative Cognitive Dysfunction

Bailie R, Christmas L, Price N, Restall J, Simpson PM, Wesnes KA (1989). Effects of temazepam premedication on cognitive recovery following alfentanil-propofol anaesthesia. *British Journal of Anaesthesia*. 63: 68-75.

Ballard C, Jones E, Gauge N, Kossakowski K, Aarsland D, Nilsen OB, Saxby BK, Lowery L, Stevens J, Wesnes K, Katsaiti E, Graham C, Arden J, Amoako D, Prophet N, Parushothaman B, Green D. (2012). Optimising depth of anaesthesia to reduce Post-Operative Cognitive Decline (POCD) in older patients undergoing elective surgery, a randomised controlled trial. *PLoS One* 7: 1-9.

Jones EL, Gauge N, Aarsland D, Nilsen OB, Lowery D, Wesnes K, Katsaiti E, Arden J, Amoako D, Prophet N, Parushothaman B, Green D, Ballard C. (2012) Analysis of NSE and S100B as biomarkers of cognitive decline following surgery in older people. *Dementia and Geriatric Cognitive Disorders* 34: 307-311.

Lowery DP, Wesnes KA, Ballard CG (2007). Subtle attentional deficits in the absence of dementia are associated with an increased risk of post-operative delirium. *Dementia and Geriatric Cognitive Disorders*. 23: 390–394.

Lowery DP, Wesnes KA, Brewster N, Ballard C. (2010). Subtle deficits of attention after surgery: Quantifying indicators of sub syndrome delirium. *International Journal of Geriatric Psychiatry* 10: 945-952.

Lowery DP, Wesnes KA, Brewster N, Ballard CG (2008). Quantifying the association between computerised measures of attention and confusion assessment method defined delirium: a prospective study of older orthopaedic surgical patients, free of dementia. *Journal of Geriatric Psychiatry*. 1-8.

Dementia (General)

Cummings JL (2000) Cholinesterase Inhibitors: Expanding Horizons. *The Lancet* 351: 2548-2549.

Ferris SH, Lucca U, Mohs R, Dubois B, Wesnes KA, Erzigkeit H, Geldmacher D, Bodick N (1997). Objective psychometric tests in clinical trials of dementia drugs. Position paper from the international working group on harmonization of dementia drug guidelines. *Alzheimer Disease and Associated Disorders an International Journal*. 11: 34-38.

Herting RL (1991). Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia. *Annals of the New York Academy of Sciences* 640: 237-240.

Holland RL, Wesnes KA (1997). Alzheimer's disease and other dementias. *Handbook of Phase I/II Clinical Drug Trials*. J. O'Grady and P. H. Joubert. Boca Raton, CRC Press: 355-372.

Micaletto M, Goetghebeur PJD, Wesnes KA (2018). Assessing Different Attentional Profiles in Alzheimer's Disease and Dementia with Lewy Bodies Using the CDR System, a Computerized Cognition Battery. Presented at the AAT-AD/PD™ Focus Meeting 2018, Torini, Italy, March 15-18, 2018.

Nicholl CG, Lynch S, Kelly CA, White L, Simpson PM, Wesnes KA, Pitt BMN (1995). The Cognitive Drug Research computerised assessment system in the evaluation of early dementia - is speed of the essence? *International Journal of Geriatric Psychiatry*. 10: 199-206.

Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK (1991). The Cognitive Drug Research computerised assessment system for demented patients: A validation study. *International Journal of Geriatric Psychiatry*. 6: 95- 102.

Simpson PM, Wesnes KA and Christmas L (1989). A computerised system for the assessment of drug-induced performance changes in young elderly or demented populations. *British Journal of Clinical Pharmacology* 27: 711P-712P.

Walker MP, Ayre GA, Cummings JL, Wesnes KA, McKeith IG, O'Brien JT, Ballard CG (2000). The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. *The British Journal of Psychiatry*. 177: 252-256.

Wesnes KA (2000). Predicting, assessing, differentiating and treating the dementias: experience in MCI and various dementias using the CDR computerised cognitive assessment system. In: B. Vellas & LJ Fitten (Eds) *Research and practice in Alzheimer's disease*, Volume 3. Serdi, Paris, 59-65.

Wesnes KA (2001). The role of attention deficits in the cognitive pathology of dementia. *Alzheimer Insights*. 7: 1-4.

Wesnes KA, Bullock R (2001). The emerging importance of attention and the speed of cognitive function in ageing and dementia research. *CPD Bulletin Old Age Psychiatry*. 3: 11-15.

Wesnes KA, Hildebrand K, Mohr E (1999). Computerised cognitive assessment. *Diagnosis and Management of Dementia: A Manual for Memory Disorders Teams*. G. W. Wilcock, R. S. Bucks and K. Rocked. Oxford, Oxford University Press: 124-136.

Zaffalon M, Wesnes KA, Petrini O (2001). Credal classification for dementia screening. In Quaglini, S., Barahona P., Andreassen, S. (Eds), *AIME '01: Proceedings of the Eighth European Conference on Artificial Intelligence in Medicine, Lecture Notes in Computer Science 2101*, Springer, 67–76.

Zaffalon M, Wesnes KA, Petrini O (2003). Reliable diagnoses of dementia by the naive credal classifier inferred from incomplete cognitive data. *Artificial Intelligence in Medicine* 29: 61-79.

Walker MP, Ayre GA, Ashton CH, Marsh VR, Wesnes KA, Perry EK, O'Brien JT, McKeith IG, Ballard CG (1999). A psychophysiological investigation of fluctuating consciousness in neurodegenerative dementias. *Human Psychopharmacology - Clinical and Experimental*. 14: 483-489.

Wesnes KA, Edgar CE. (2014). The role of human cognitive neuroscience in drug discovery for the dementias. *Current Opinion in Pharmacology* 14: 62-73.

Wesnes KA (2014). Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: The case for equal opportunity. *Alzheimer's Research & Therapy* 6: 58 DOI: 10.1186/s13195-014-0058-1

Wesnes KA, Harrison JE (2003). The evaluation of cognitive function in the dementias: methodological and regulatory considerations. *Dialogues in Clinical Neuroscience: Dementia*. 5: 77-88.

Wesnes KA (2008). Assessing change in cognitive function in dementia: The relative utilities of the Alzheimer's Disease Assessment Scale – cognitive subscale and the Cognitive Drug Research system. *Neurodegenerative Disease*. 5: 261-263.

Parkinson's Disease Dementia and Dementia with Lewy Bodies

Almeida OP, Burton EJ, McKeith I, Gholkar A, Burn D, O'Brien JT (2003). MRI Study of Caudate Nucleus Volume in Parkinson's disease with and without Dementia with Lewy Bodies and Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*. 16: 57-63.

Ballard CG, Aarsland D, McKeith IG, O'Brien JT, Gray A, Cormack F, Burn D, Cassidy T, Starfeldt R, Larsen JP, Brown R, Tovee M (2002). Fluctuations in attention: PD dementia vs. DLB with Parkinsonism. *Neurology*. 59: 1714-1720.

Ballard CG, O'Brien JT, Gray A, Cormack F, Ayre G, Rowan EN, Thompson P, Bucks R, McKeith IG, Walker M, Tovee M (2001). Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. *Archives of Neurology*. 58: 977-982.

Ballard CG, Walker M, O'Brien JT, Rowan EN, McKeith IG (2001). The characterisation and impact of 'fluctuating' cognition in dementia with Lewy bodies and Alzheimer's disease. *International Journal of Geriatric Psychiatry*. 16: 494-498.

Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, Lane RM (2008). Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. *Movement Disorders*. 23: 1532-1540.

Bronnick K, Ehrt U, Emre M, De Deyn PP, Wesnes KA, Tekin S, Aarsland D (2006). Attentional deficits affect activities of daily living in dementia associated with Parkinson's disease. *Journal of Neurology Neurosurgery & Psychiatry*. 77: 1136–1142.

Burn D, Emre M, McKeith IG, De Deyn PP, Aarsland D, Hsu C, Lane R (2006). Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. *Movement disorders*. 21: 1899-1907.

Corani G, Edgar C, Marshall I D, Wesnes KA, Zaffalon M (2006). Classification of Dementia Types from Cognitive Profiles Data. In *ECML 2006: Proceedings of the seventeenth European Conference on machine Learning, Lecture Notes in Computer Science 4213*, Springer, Berlin, 470–477.

Dujardin K, Devos D, Duhem S, Desté A, Marié R-M, Durif F, Lacomblez L, Touchon J, Pollak P, Péré J-J (2006). Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease. *Journal of Neurology* 253: 1154-1159.

Edwards K, Hershey L, Wray L, Bednarczyk E, Lichter D, Farlow M, Johnson M (2004). Efficacy and safety of Galantamine in patients with Dementia with Lewy Bodies: A 12-Week Interim Analysis. *Dementia and Geriatric Cognitive Disorders*. 17: 40-48.

Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M, Pasquier F, Johnson S (2007). Efficacy and safety of Galantamine in patients with Dementia with Lewy Bodies: A 24-week open label study. *Dementia and Geriatric Cognitive Disorders*. 23: 401-405.

Emre M (2004) Dementia Associated with Parkinson's disease. *Lancet Neurology*. 2: 229-237.

Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R (2004). Rivastigmine for dementia associated with Parkinson's disease. *The New England Journal of Medicine*. 351: 2509-2518.

Emre M, Aarsland D, Brown R et al. (2007). Clinical Diagnostic Criteria for Dementia Associated with Parkinson's Disease. *Movement Disorders* 22: 1689-1707.

Goetghebuer PJD, Micaletto M, Wesnes KA (2018) Computerized Assessment of Attentional Processes and Drug Efficacy in Parkinson's Disease Dementia Using the CDR System. Presented at the AAT-AD/PD™ Focus Meeting 2018, Torini, Italy, March 15-18, 2018.

Harvey PD, Ferris SH, Cummings JL, Wesnes KA, Hsu C, Lane RM, Tekin S (2010) Evaluation of Dementia Rating Scales in Parkinson's Disease Dementia. *American Journal of Alzheimer's Disease and Other Dementias* 25:142-148

McKeith IG, Del Ser T, Spano P, Emre M, Wesnes KA, Anand R, Cicin-Sain A, Ferrara R, Spiegel R (2000). Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. *Lancet*. 356: 2031-2036.

McKeith IG, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O'Brien JT, Playfer J, Reid W (2004). Dementia with Lewy bodies. *Lancet Neurology*. 3: 19-28.

Molloy S, Rowan EN, O'Brien JT, McKeith IG, Wesnes KA, Burn DJ (2006). The effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. *Journal of Neurology Neurosurgery & Psychiatry*. 77: 1323-1328.

McKeith IG, Wesnes KA, Perry E, Ferrara R (2004). Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy Bodies. *Dementia and Geriatric Cognitive Disorders*. 18: 94-100.

Mosimann UP, Mather G, Wesnes KA, O'Brien JT, Burn DJ, McKeith IG (2004). Visual perception in Parkinson disease dementia and dementia with Lewy bodies. *Neurology*. 63: 2091-2096.

Press DZ (2004). Parkinson's Disease Dementia: A First Step? *New England Journal of Medicine*. 351: 2547-2549.

Rowan EN, McKeith IG, Saxby BK, O'Brien JT, Burn D, Mosimann U, Newby J, Daniel S, Sanders J, Wesnes KA (2007). Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with Dementia and Dementia with Lewy Bodies. *Dementia and Geriatric Cognitive Disorders*. 23: 161- 167.

Schmitt FA, Aarsland D, Brønnick K et al, (2010). Evaluating Rivastigmine in Mild-to-Moderate Parkinson's Disease Dementia Using ADAS-Cog Items. *American Journal of Alzheimer's Disease and Other Dementias* 25: 407- 413

Tekin S, Lane R (2005). Rivastigmine in the treatment of dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study. *Progress in Neurotherapeutics and Neuropsychopharmacology*. 1: 1-13.

Wesnes KA, McKeith IG, Edgar C, Emre M, Lane R (2005). Benefits of rivastigmine on attention in dementia associated with Parkinson disease. *Neurology*. 65: 1654-1656.

Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, Cicin-Sain A, Anand R, Spiegel R (2002). Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system. *Dementia and Geriatric Cognitive Disorders*. 13: 183-192.

Williams G, Barker RA (2007). Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. *Nature Clinical Practice Neurology*. 3: 250-251.

Wesnes KA, Aarsland D, Ballard C, Londos E. (2014). Memantine improves attention and verbal episodic memory in patients with Parkinson's disease dementia and dementia with Lewy bodies: A randomised, doubleblind, placebo-controlled, multicentre trial. *International Journal of Geriatric Psychiatry* DOI: 10.1002/gps.4109

Walker MP, Ayre GA, Cummings JL, Wesnes KA, McKeith IG, O'Brien JT, Ballard CG (2000). Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. *Neurology*. 54: 1616-1625.

Walker MP, Ayre GA, Perry EK, Wesnes KA, McKeith IG, Tovee M, Edwardson JA, Ballard CG (2000). Quantification and characterization of fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*. 11: 327-335.

Watson R, Colloby SJ, Blamire AM, Wesnes KA, Wood J, O'Brien JT (2017). Does attentional dysfunction and thalamic atrophy predict decline in dementia with Lewy bodies? *Parkinsonism Relat Disord*. 45:69-74. doi: 10.1016/j.parkreldis.2017.10.006.

Wesnes KA (2007). Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease. *Drugs of Today*. 43: 349-359.

Alzheimer's Disease

Allain H, Neuman E, Malbezin M, Salzman V, Guez D, Wesnes KA, Gandon JM (1997). Bridging study of S12024 in 53 in-patients with Alzheimer's disease. *Journal of the American Geriatrics Society*. 45: 125-126.

Ellis JR, Villemagne VL, Nathan PJ, Mulligan RS, Gong SJ, Chan JG, Sachinidis J, O'Keefe GJ, Pathmaraj K, Wesnes KA, Savage G, Rowe CC (2008). Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: A 2-[18F]fluoro-A-85380 PET study. *Neurobiology of Learning and Memory*. 90: 404 - 412.

Fakouhi TD, Jhee SS, Sramek JJ, Benes C, Schwartz P, Hantsburger G, Herting R, Swabb EA, Cutler NR (1995). Evaluation of cycloserine in the treatment of Alzheimer's disease. *Journal of Geriatric Psychiatry and Neurology*. 8: 226-230.

Frolich L, Ashwood T, Nilsson J, Eckerwall G (2011) Effects of AZD3480 on Cognition in Patients with Mild-to- Moderate Alzheimer's Disease: A Phase IIb Dose-Finding Study. *Journal of Alzheimer's Disease* 24: 363– 374

Galvin JE, Cornblatt B, Newhouse P, Ancoli-Israel S, Wesnes KA, Williamson D, Zhu Y, Sorra K, Amatniek J (2008). Effects of Galantamine on measures of attention: Results from 2 clinical trials in Alzheimer disease patients with comparisons to Donepezil. *Alzheimer Disease and Associated Disorders*. 22: 30-38.

Geerts H. (2006). Ispronicline (Targacept). *Curr Opin Investig Drugs* 1:60-69

Goa KL, Fitton A. (1994). Velnacrine in Alzheimer's Disease: An Initial Appraisal of its Clinical Potential. *CNS Drugs* 1: 232-240.

Goetghebeur PJD, Wesnes KA, Targum SD (2018). D-Cycloserine improves difficult discriminations in a pattern separation task in Alzheimer's disease: Implications for dentate gyrus activity and neurogenesis. Presented at the 11th Clinical Trials on Alzheimer's Disease (CTAD), Barcelona, Spain, October 24-27, 2018.

Mohr E, Knott V, Sampson M, Wesnes KA, Herting R, Mendis T (1995). Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. *Clinical Neuropharmacology*. 18: 28-38.

Mohr E, Walker D, Randolph C, Sampson M, Mendis T (1996). The utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia. *International Psychogeriatrics*. 8: 397-411.

O'Brien JT, Wiseman R, Burton EJ, Barber B, Wesnes KA, Saxby BK, Ford GA (2002). Cognitive associations of subcortical white matter lesions in older people. *Annals of New York Academy of Sciences*. 977: 436-444.

O'Brien KK, Saxby BK, Ballard CG, Grace J, Harrington F, Ford GA, O'Brien JT, Swan AG, Fairbairn AF, Wesnes KA, del Ser T, Edwardson JA, Morris CM, McKeith IG (2003). Regulation of attention and response to therapy in dementia by butyrylcholinesterase. *Pharmacogenetics*. 13: 231-239.

Rinne JO, Wesnes K, Cummings JL, Hakulinen P, Hallikainen M, Hänninen J, Murphy M, Riordan H, Scheinin M, Soininen H, Rouru J (2016) . Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease. *Alzheimers Dement (N Y)*. 3(1): 1-9. doi: 10.1016/j.trci.2016.11.004.

Siegfried K (1991). First clinical impressions with an ACTH analogue (HOE 427) in the treatment of Alzheimer's disease. *Annals of the New York Academy of Sciences* 640: 260-283.

Siegfried KR (1993). Pharmacodynamic and early clinical studies with velnacrine. *Acta Neurol Scand* 149: 26-28.

Siegfried KR (1993). The pharmacodynamics of velnacrine: Results and conclusions from clinical studies in healthy subjects and patients with Alzheimer's disease. In: Wilcock GK (Ed.) *The Management of Alzheimer's Disease*. Wrightson Biomedical Publishing, pp 189-201.

Templeton L, Barker A, Wesnes KA, Wilkinson D (1999). A double-blind, placebo-controlled single dose trial of intravenous flumazenil in Alzheimer's disease. *Human Psychopharmacology - Clinical and Experimental*. 14: 239-245.

Vellas B, Cunha L, Gertz HJ, De Deyn PP, Wesnes KA, Hammond G, Schwalen S (2005). Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. *Current Medical Research and Opinion*. 21: 1423-1429.

Wesnes KA, Edgar C, Andreasen N, Annas P, Basun H, Lannfelt L, Zetterberg H, Blennow K, Minthon L (2010) Computerised cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease. *Acta Neurologica Scandinavica* 122: 270-277.

Wesnes KA, Annas P, Basun H, Edgar CE, Blennow K. (2014). Object Pattern Separation data in Alzheimer's patients consistent with disrupted hippocampal dentate gyrus activity suggesting compromised neurogenesis is related to APOE status and CSF A β 42. *Alzheimer's Research & Therapy* 6:20.

Schizophrenia

McIntyre RS, Daniel DG, Vieta E, Laszlovszky I, Goetghebeur PJ, Earley WR, Patel MD (2022). The efficacy of cariprazine on cognition: a post hoc analysis from phase II/III clinical trials in bipolar mania, bipolar depression, and schizophrenia. *CNS Spectr*. 2022 Feb 23;1-12. Poster

McIntyre RS, Daniel DG, Earley WR, Patel MD, Laszlovszky I, Goetghebeur P, Wesnes KA (2019). Effects of Cariprazine on Attentional Processes in Patients With Schizophrenia: Post Hoc Analysis From a Randomized, Controlled Phase III Study. 172nd Annual Meeting of the American Psychiatry Association San Francisco, California, USA. May 18–22, 2019

Wesnes K, Brooker H, Edgar C, Hassman H (2010). The Profile of Cognitive Impairment in Schizophrenia: Implications for Therapeutic Treatment Strategies. 2nd Biennial Schizophrenia International Research Conference, April 10-14, 2010, Florence, Italy. Poster

M. C. Bardwell, H. Hassman, D. Krefetz, M. Pinho, S. Satek, H. Brooker, B. K. Saxby, J. Ferguson, K. Wesnes (2009). A Comparison of the Matrics Consensus Cognitive Battery (MCCB) with the Cognitive Drug Research (CDR) System in Schizophrenia. Poster.

Macek TA, McCue M, Xie J, Wesnes K, Boeijinga P (2017). Changes in EEG Markers by TAK-063 in Subjects With Stable Schizophrenia Have Different Temporal Relationships With Changes in Working Memory. SIRS. Poster

Wesnes K, Wojciak R, Feaster T, McNamara C, Butler A, Krefetz D, Pittman D, Fogel J, Kramer S, Erica Ridolfi E, Hassman, H (2012). Validity, reliability and everyday relevance of a new executive function task for use in clinical trials in schizophrenia. 28th International Congress on Clinical Neuro-psychopharmacology (CINP), Stockholm Sweden, 3-7 June 2012.

Hassman H, Krefetz D, Kelly B, Satek S, Keith Wesnes K, Ferguson, J. The Use of the CDR Computerized Schizophrenia Battery to Measure Cognitive Function in Schizophrenia Clinical Trials. Poster

Hassman H, Fruncillo R, Glass S, Krefetz D, Pinho M, Wesnes KA (2010). The Implications Of The Cognitive Deficit Profile In Schizophrenia For Therapeutic Strategies. ISCTM. Poster.

Wesnes KA, Edgar C, Brownstein L, Hassman H, Evins AE (2012). The Central Role of Attention and Information Processing Deficits in the Profile of Cognitive Dysfunction in Schizophrenia. 3rd Biennial Schizophrenia International Research Society Conference (SIRS) - Florence, Italy 14-18 April 2012

Stroke & Vascular Dementia

Akinyemi RO, Allan L, Owolabi MO et al. (2014). Profile and determinants of vascular cognitive impairment in African stroke survivors: The CogFAST Nigeria Study. *Journal of the Neurological Sciences* 346: 241-249.

Ballard CG, Morris CM, Rao H, O'Brien JT, Barber R, Stephens S, Rowan EN, Gibson A, Kalaria RN, Kenny RA (2004). APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment. *Neurology*. 63: 1399-1402.

Ballard CG, Rowan EN, Stephens S, Kalaria R, Kenny RA (2003), Prospective Follow-Up Study Between 3 and 15 Months After Stroke: Improvements and Decline in Cognitive Function Among Dementia-Free Stroke Survivors >75 Years of Age. *Stroke* 34: 2440-2445.

Ballard CG, Stephens S, Kenny RA, Kalaria R, Tovee M, O'Brien JT (2003). Profile of neuropsychological deficits in older stroke survivors without dementia. *Dementia and Geriatric Cognitive Disorders*. 16: 52-56.

Ballard CG, Stephens S, McLaren A, Wesnes KA, Kenny R (2003). Mild cognitive impairment and vascular cognitive impairment in stroke patients. *International Psychogeriatrics*. 15: 123-126.

Ballard CG, Stephens S, McLaren A, Wesnes KA, Kenny RA, Burton E, O'Brien JT, Kalaria R (2002). Neuropsychological deficits in older stroke patients. *Annals of the New York Academy of Sciences*. 977: 179-182.

Burton EJ, Kenny RA, O'Brien JT, Stephens S, Bradbury M, Rowan EN, Kalaria R, Firbank M, Wesnes KA, Ballard CG (2004). White matter hyperintensities are associated with impairment of memory, attention, and global cognitive performance in older stroke patients. *Stroke*. 35: 1270-1275.

Kure CE, Rosenfeldt FL, Scholey AB, Pipingas A, Kaye DM, Bergin PJ, Croft KD, Wesnes KA, Myers SP, Stough C (2016). Relationships Among Cognitive Function and Cerebral Blood Flow, Oxidative Stress, and Inflammation in Older Heart Failure Patients. *J Card Fail*. 22(7): 548-59. doi: 10.1016/j.cardfail.2016.03.006.

Rowan EN, Dickinson HO, Stephens S, Ballard CG, Kalaria R, Kenny RA (2007). Homocysteine and post-stroke cognitive decline. *Age and Ageing*. 36: 339-343.

Rowan EN, Morris CM, Stephens S, Ballard CG, Dickinson H, Rao H, Saxby BK, McLaren AT, Kalaria RN, Kenny RA (2005). Impact of hypertension and apolipoprotein E4 on post-stroke cognition in subjects >75 years of age. *Stroke*. 36: 1864-1868.

Pettersen R, Saxby BK, Wyller TB (2007). Post-stroke urinary incontinence: one-year outcome and relationships with measures of attentiveness. *Journal of the American Geriatrics Society*. 55: 1571-1577.

Stephens S, Kenny RA, Rowan EN, Allan L, Kalaria RN, Bradbury M, Ballard CG (2004). Neuropsychological characteristics of mild vascular cognitive impairment and dementia after stroke. *International Journal of Geriatric Psychiatry*. 19: 1053-1057.

McGuinness B, Barrett SL, Craig D, et al. (2010). Attention deficits in Alzheimer's disease and Vascular Dementia. *J Neurol Neurosurg Psychiatry* 81: 157-159

McGuinness B, Barrett SL, Craig D, et al. (2010). Executive functioning in Alzheimer's disease and vascular dementia. *International Journal of Geriatric Psychiatry* 25: 562-568.

Anaesthesiology, Cardiac Surgery

Fearn SJ, Hutchinson S, Riding G, Hill-Wilson G, Wesnes KA, McCollum CN (2003). Carotid endarterectomy improves cognitive function in patients with exhausted cerebrovascular reserve. *European Journal of Vascular and Endovascular Surgery*. 26: 529-536.

Fearn SJ, Pole R, Wesnes KA, Faragher EB, Hooper TL, McCollum CN (2001). Cerebral injury during cardiopulmonary bypass: emboli impair memory. *The Journal of Thoracic and Cardiovascular Surgery*. 121: 1150-1160.

Girdler NM, Fairbrother KJ, Lyne JP, Neave N, Scholey AB, Hargaden N, Wesnes KA, Engler J, Rotherham NA (2002). A randomised crossover trial of post-operative cognitive and psychomotor recovery from benzodiazepine sedation: effects of reversal with flumazenil over a prolonged recovery period. *British Dental Journal*. 192: 335-339.

Girdler NM, Lyne JP, Wallace R, Neave N, Scholey AB, Wesnes KA, Herman C (2002). A randomised, controlled trial of cognitive and psychomotor recovery from midazolam sedation following reversal with oral flumazenil. *Anaesthesia*. 57: 868-876.

Thompson JM, Neave N, Moss MC, Scholey AB, Wesnes KA, Girdler NM (1999). Cognitive properties of sedation agents: comparison of the effects of nitrous oxide and midazolam on memory and mood. *British Dental Journal*. 187: 557-562.

van den Goor JM, Saxby BK, Tijssen JG, Wesnes KA, deMol BA, Nieuwland R (2008). Improvement of cognitive test performance in patients undergoing primary CABG and other CPB-assisted cardiac procedures. *Perfusion*. 23: 267-273.

Kure CE, Rosenfeldt FL, Scholey AB, Pipingas A, Kaye DM, Bergin PJ, Croft KD, Wesnes KA, Myers SP, Stough C. (2016). Relationships Among Cognitive Function and Cerebral Blood Flow, Oxidative Stress, and Inflammation in Older Heart Failure Patients. *J Card Fail.* 22(7):548-59.

Attention Deficit Hyperactivity Disorder

Lloyd A, Brett D, Wesnes K (2010). Coherence training in children with Attention-Deficit Disorder: Cognitive function and behavioral changes. *Alternative Therapies* 16: 34-42.

Wilens TE, Klint T, Adler L, West S, Wesnes KA, Graff O, Mikkelsen B (2008). A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. *Behavioural and Brain Functions.* 4: 24.

Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, West SA (2006). ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. *Biological Psychiatry.* 59: 1065-1070.

Chronic Fatigue Syndrome

McCue PM, Scholey AB, Herman C, Wesnes KA (2002). Validation of a telephone cognitive assessment test battery for use in chronic fatigue syndrome. *Journal of Telemedicine & Telecare.* 8: 337-343.

Russell-Blacker CV, Greenwood DT, Wesnes KA, Wilson R, Woodward C, Howe I, Ali T (2004). Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial. *The Journal of the American Medical Association.* 292: 1195-1204.

Depression

Camfield DA, Fontana R, Wesnes KA, Mills J, Croft RJ (2018) Effects of aging and depression on mnemonic discrimination ability. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn.* 25(3): 464-483. doi: 10.1080/13825585.2017.1325827.

Ferguson JM, Wesnes KA, Schwartz GE (2003). Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. *International Clinical Psychopharmacology.* 18: 9-14.

Reddy S, Fayyad R, Edgar CJ, Guico-Pabia CJ, Wesnes K (2015). The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial. *Journal of Psychopharmacology* 30: 559-567.

Sambunaris A, Bose A, Gommoll C, Chen C, Greenberg WM, Zukin S, Sheehan DV (2012). Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran SR in Patients With Major Depressive Disorder. Presented at the 51st Annual Meeting of the American College of Neuropsychopharmacology December 2-6, 2012 Hollywood, Florida

Vasudev A, Saxby BK, Colloby S, O' Brien JT, Firbank MJ, Brooker H, Wesnes K, Thomas AJ. (2012) Relationship between cognition, magnetic resonance white matter hyperintensities and cardiovascular autonomic changes in late life depression. *American Journal of Geriatric Psychiatry* 20:691-699.

Wesnes KA, Hopkins S, Brooker HJ, Koblan KS (2016). Differences in memory function between 5-HT1A receptor genotypes in patients with major depressive disorder. *CNS Spectrums* 21(5):379-384.

Wesnes KA, Gommoll C, Chen C, Sambunaris A, McIntyre RS, Harvey PD (2017). Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study. *Int Clin Psychopharmacol.* 32(2): 72-79. doi: 10.1097/YIC.000000000000157.

Drug Abuse

Hendriks V, van den Brink W, Blanken P, Bosman I, van Ree J (2001). Heroin self-administration by means of 'chasing the dragon': pharmacodynamics and bioavailability of inhaled heroin. *European Neuropsychopharmacology.* 11: 241-252.

Morgan PT, Pace-Schott EF, Sahul ZH, Coric V, Stickgold R, Malison RT (2006). Sleep, sleep-dependent procedural learning and vigilance in chronic cocaine users: Evidence for occult insomnia. *Drug and Alcohol Dependence.* 82: 238-249.

Pace-Schott E, Morgan T, Robert T, Hart C, Edgar C, Walker M, Stickgold R (2008). Cocaine users differ from normals on cognitive tasks which show poorer performance during drug abstinence. *The American Journal of Drug and Alcohol Abuse.* 34: 109–121.

Pace-Schott EF, Stickgold R, Muzur A, Wigren PE, Ward AS, Hart CL, Walker M, Edgar C, Hobson JA (2005). Cognitive performance by humans during a smoked cocaine binge-abstinence cycle. *The American Journal of Drug and Alcohol Abuse.* 31: 571-591.

Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes KA (1998). Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits. *Journal of Psychopharmacology.* 12: 79-83.

Silber BY, Croft RJ, Papafotiou K, Stough C (2006). The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance. *Psychopharmacology* 187: 154-169.

Stough C, King R, Papafotiou K, Swann P, Ogden E, Wesnes K, Downey L A (2012) The acute effects of 3,4- methylenedioxymethamphetamine and d-methamphetamine on human cognitive functioning. *Psychopharmacology* 220: 799-807. *Eating Disorders*

Anorexia

Bosanac P, Kurlender S, Norman T, Hallam K, Wesnes KA, Manktelow TC, Burrows G (2007). An open-label study of quetiapine in anorexia nervosa. *Human Psychopharmacology.* 22: 223–230.

Bosanac P, Kurlender S, Stojanovska L, Hallam K, Norman T, McGrath C, Burrows G, Wesnes K, Manktelow T, Olver J. (2007). Neuropsychological study of underweight and weight-recovered anorexia nervosa compared with bulimia nervosa and normal controls. *International Journal of Eating Disorders* 40: 613- 621.

Seed JA, McCue PM, Wesnes KA, Dahabra S, Young AH (2002). Basal activity of the HPA axis and cognitive function in anorexia nervosa. *International Journal of Neuropsychopharmacology.* 5: 17-25.

Epilepsy

Wesnes KA, Edgar C, Dean ADP, Wroe SJ (2009). The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy. *Epilepsy and Behaviour.* 14: 522-528.

Meador KJ, Yang H, Piña-Garza JE, Laurenza A, Kumar D, Wesnes KA (2016). Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial. *Epilepsia* doi: 0.1111/epi.13279

Jóźwiak S, Veggiotti P, Moreira J, Gama H, Rocha F, Soares-da-Silva P (2018). Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures. *Epilepsy Behav.* 81:1-11. doi: 10.1016/j.yebeh.2018.01.029.

Busner J & Wesnes KA (2013) Differential effects on attention over 24 weeks of a NMDA antagonist versus carbamazepine in paediatric epilepsy patients. Poster presentation at the 26th European College of Neuropsychopharmacology (ECNP) Meeting in Barcelona, Spain, 5-9 October 2013

Environmental Stressors and Toxins

Bucks R, Gidron Y, Harris P, Teeling J, Wesnes KA, Perry H (2008). Selective effects of upper respiratory tract infection on cognition, mood and emotion processing: a prospective study. *Brain, Behaviour and Immunity.* 22: 399-407.

Coley DA, Greeves R, Saxby BK (2007). The effect of low ventilation rates on the cognitive function of a primary school class. *International Journal of Ventilation.* 6: 107-112.

Gidron Y, Hall P, Wesnes KA, Bucks RS (2010) Does a neuropsychological index of hemispheric lateralization predict onset of upper-respiratory tract infectious symptoms? *British Journal of Health Psychology* 15: 469-478.

Maldonado EF, Fernandez FJ, Trainee MV, Wesnes KA, Petrini O, Zangara A, Enguix A, Ambrosetti L (2008). Cognitive performance and morning levels of salivary cortisol and α -amylase in children reporting high vs. low daily stress perception. *The Spanish Journal of Psychology.* 11: 3-15.

Neave N, Emmett J, Moss M, Ayton R, Scholey AB, Wesnes KA (2004). The effects of protective helmet use on physiology and cognition in young cricketers. *Applied Cognitive Psychology.* 18: 1181-1193.

Neave N, Scholey AB, Emmett JR, Moss M, Kennedy DO, Wesnes KA (2001). Water ingestion improves subjective alertness, but has no effect on cognitive performance in dehydrated healthy young volunteers. *Appetite.* 37(3): 255-256.

Parry SW, Steen N, Baptist M, Kenny RA (2005). Amnesia for loss of consciousness in carotid sinus syndrome. *Journal of the American College of Cardiology.* 45: 1840–1843.

Preece AW, Goodfellow S, Wright MG, Butler SR, Dunn EJ, Johnson Y, Manktelow TC, Wesnes KA (2005). Effect of 902 MHz mobile phone transmission on cognitive function in children. *Bioelectromagnetics.* 7: 138-143.

Preece AW, Iwi G, Davies-Smith A, Wesnes KA, Butler S, Lim E, Varey A (1999). Effect of a 915-MHz simulated mobile phone signal on cognitive function in man. *International Journal of Radiation Biology.* 75: 447- 456.

Preece AW, Wesnes KA, Iwi GR (1998). The effect of a 50 Hz magnetic field on cognitive function in humans. *International Journal of Radiation Biology.* 74: 463-470.

Ritchie KA, Gilmour WH, Macdonald EB, Burke FJT, McGowan DA, Dale IM, Hammersley R, Hamilton RM, Binnie V, Collington D (2002). Health and neuropsychological functioning of dentists exposed to mercury. *Journal of Occupational & Environmental Medicine.* 59: 287–293.

Ritchie KA, Macdonald EB, Hammersley R, O'Neil JM, McGowan DA, Dale IM, Wesnes KA (1995). A pilot study of the effect of low level exposure to mercury on the health of dental surgeons. *Occupation & Environmental Medicine*. 52: 813-817.

Simmons SE, Saxby BK, McGlone FP, Jones DA (2008). The effect of passive heating and head cooling on perception, cardiovascular function and cognitive performance in the heat. *European Journal of Applied Physiology*. 104: 271-280. Estradiol Therapy

Bartholomeusz CF, Wesnes KA, Kulkarni J, Vitetta L, Croft RJ, Nathan PJ (2008). Estradiol treatment and its interaction with the cholinergic system: Effects on cognitive function in healthy young women. *Hormones and Behaviour*. 54: 684-693.

Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C (2005). Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. *Psychoneuroendocrinology*. 30: 309-315.

Genetic Studies

Ballard CG, Morris CM, Rao H, O'Brien JT, Barber R, Stephens S, Rowan EN, Gibson A, Kalaria RN, Kenny RA (2004). APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment. *Neurology*. 63: 1399-1402.

Lieberman JN, Stewart WF, Wesnes KA, Troncoso J (2002). Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury. *The Journal of Neurology*. 58: 1038-1044.

O'Brien KK, Saxby BK, Ballard CG, Grace J, Harrington F, Ford GA, O'Brien JT, Swan AG, Fairbairn AF, Wesnes KA, del Ser T, Edwardson JA, Morris CM, McKeith IG (2003). Regulation of attention and response to therapy in dementia by butyrylcholinesterase. *Pharmacogenetics*. 13: 231-239.

Pomara N, Willoughby L, Wesnes KA, Greenblatt DJ, Sidtis JJ (2005). Apolipoprotein E epsilon4 allele and lorazepam effects on memory in high-functioning older adults. *Archives of General Psychiatry*. 62: 209-216.

Pomara N, Willoughby LM, Hashim A, Sershen H, Sidtis JJ, Wesnes KA, Greenblatt DJ, Lajtha A (2004). Effects of acute lorazepam administration on aminergic activity in normal elderly subjects: relationship to performance effects and apolipoprotein genotype. *Neurochemical Research*. 29: 1391-1398.

Pomara N, Willoughby LM, Wesnes KA, Sidtis JJ (2004). Increased anticholinergic challenge-induced memory impairment associated with the APOE-epsilon4 allele in the elderly: a controlled pilot study. *Neuropsychopharmacology*. 29: 403-409.

Rowan EN, Morris CM, Stephens S, Ballard CG, Dickinson H, Rao H, Saxby BK, McLaren AT, Kalaria RN, Kenny RA (2005). Impact of hypertension and apolipoprotein E4 on post-stroke cognition in subjects >75 years of age. *Stroke*. 36: 1864-1868.

Hepatic Encephalopathy

Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes KA, Thomas HC, Taylor-Robinson SD (2005). A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. *AIDS The Official Journal of the International AIDS Society*. 19: S53-63.

Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, Wesnes KA, Taylor-Robinson SD (2002). Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. *Hepatology*. 35: 433-439.

Forton MD, Hamilton G, Allsop JM, Grover VP, Wesnes KA, O'Sullivan C, Thomas HC, Taylor-Robinson SD (2008). Cerebral immune activation in chronic hepatitis C infection: A magnetic resonance spectroscopy study. *Journal of Hepatology*. 49: 316-322.

Forton DM (2011). Hepatitis C treatment – Clearing the mind. *Journal of Hepatology* 56: 513 – 514.

Mardini H, Saxby BK, Record CO (2006). Computerised or paper and pencil psychometric tests for the assessment of hepatic encephalopathy? *Hepatic Encephalopathy and Nitrogen Metabolism*. D. Häussinger, G. Kirchels and F. Schless, Springer. 37: 474-479.

Mardini H, Saxby BK, Record CO (2008). Computerized psychometric testing in minimal encephalopathy and modulation by Nitrogen challenge and liver transplant. *Gastroenterology*. 135: 1582-1590.

Mardini H, Smith FE, Record CO, Blamire AM (2011). Magnetic resonance quantification of water and metabolites in the brain of cirrhotics following induced hyperammonaemia. *Journal of Hepatology* 54: 1154–1160.

Masson S, Mardini HD, Rose JD, Record CO (2008). Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. *Quarterly Journal of Medicine*. 6: 493 – 501.

McPhail MJW, Leech R, Grover VPB, Fitzpatrick JA, Dhanjal NS, Crossey MME, Saxby BK, Wesnes K, Dresner MA, Waldman AD, Thomas HC, Taylor-Robinson SD. (2013). Novel modulation of neural activation following treatment of minimal hepatic encephalopathy: A sequential fMRI study. *Neurology* 80:1–7.

Hypertension

Firbank MJ, Wiseman RM, Burton EJ, Saxby BK, O'Brien J T, Ford GA (2007). Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure: Brain atrophy, WMH change and blood pressure. *Journal of Neurology*. 254: 713-721.

Harrington F, Saxby BK, McKeith IG, Wesnes KA, Ford GA (2000). Cognitive performance in hypertensive and normotensive older subjects. *Hypertension*. 36: 1079-1082.

Hearing S, Wesnes KA, Bowman C (1999). Beta-blockers and cognitive function in elderly hypertensive patients: Withdrawal and consequences of ACE inhibitor substitution. *International Journal of Geriatric Psychopharmacology*. 2: 13-17.

Narayan SK, Saxby BK, Firbank MJ et al (2011). Plasma homocysteine and cognitive decline in older hypertensive subjects. *International Psychogeriatrics* 23: 1607–1615.

Pase MP, Pipingas A, Kras M, Nolidin K, Gibbs AL, Wesnes KA, Scholey AB, Stough C (2010) Healthy Middle-Aged Individuals are Vulnerable to Cognitive Deficits as a Result of Increased Arterial Stiffness. *Journal of Hypertension* 28: 1724-1729.

Saxby BK, Harrington F, McKeith IG, Wesnes KA, Ford GA (2003). Effects of hypertension on attention, memory, and executive function in older adults. *Health Psychology*. 22: 587-591.

Saxby BK, Harrington F, Wesnes KA, McKeith IG, Ford GA (2008). Candesartan and cognitive decline in older patients with hypertension. *Neurology*. 70: 1858-1866.

Rowan EN, Morris CM, Stephens S, Ballard C et al. (2005). Impact of hypertension and apolipoprotein E4 on poststroke cognition in subjects >75 years of age. *Stroke*. 36: 1864-1868.

Imaging Studies

Almeida OP, Burton EJ, McKeith I, Gholkar A, Burn D, O'Brien JT (2003). MRI Study of Caudate Nucleus Volume in Parkinson's Disease with and without Dementia with Lewy Bodies and Alzheimer's Disease. *Dementia and Geriatric Cognitive Disorders*. 16: 57-63.

Ballard CG, Aarsland D, McKeith IG, O'Brien JT, Gray A, Cormack F, Burn D, Cassidy T, Starfeldt R, Larsen JP, Brown R, Tovee M (2002). Fluctuations in attention: PD dementia vs. DLB with Parkinsonism. *Neurology*. 59: 1714-1720.

Burton EJ, Kenny RA, O'Brien JT, Stephens S, Bradbury M, Rowan EN, Kalaria R, Firbank M, Wesnes KA, Ballard CG (2004). White matter hyperintensities are associated with impairment of memory, attention, and global cognitive performance in older stroke patients. *Stroke*. 35: 1270-1275.

Firbank MJ, Wiseman RM, Burton EJ, Saxby BK, O'Brien J T, Ford GA (2007). Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure: Brain atrophy, WMH change and blood pressure. *Journal of Neurology*. 254: 713-721.

Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes KA, Thomas HC, Taylor-Robinson SD (2005). A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. *AIDS The Official Journal of the International AIDS Society*. 19: S53-63.

Forton MD, Hamilton G, Allsop JM, Grover VP, Wesnes KA, O'Sullivan C, Thomas HC, Taylor-Robinson SD (2008). Cerebral immune activation in chronic hepatitis C infection: A magnetic resonance spectroscopy study. *Journal of Hepatology*. 49: 316-322.

O'Brien JT, Wiseman R, Burton EJ, Barber B, Wesnes KA, Saxby BK, Ford GA (2002). Cognitive associations of subcortical white matter lesions in older people. *Annals of New York Academy of Sciences*. 977: 436- 444.

Kidney Disease

Altmann P, Barnett ME, Finn WF (2007). Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. *Kidney International* 71: 252-259.

Multiple Sclerosis

Edgar C, Jongen PJ, Sanders E, Sindic C, Goffette S, Dupuis M, Jacquerye P, Guillaume D, Reznik R, Wesnes K. (2011). Cognitive performance in relapsing remitting multiple sclerosis patients during treatment with intramuscular interferon-beta-1a in daily practice. *BMC Neurology* 11: 68.

Jongen PJ, Wesnes K, van Geel B, Pop P, Sanders E, Schrijver H, Visser LH, Gilhuis J, Sinnige O, Brands A, COGNISEC study group. (2014). Relationship between Working Hours and Power of Attention, Memory, Fatigue, Depression and Self-Efficacy One Year after Diagnosis of Clinically Isolated Syndrome and Relapsing Remitting Multiple Sclerosis. PLoS ONE 9(5): e96444. DOI: 10.1371/journal.pone.0096444

Jongen PJ, Wesnes KA, Van Geel BM, Pop P, Schrijver H, Visser LH, Gilhuis J, Sinnige L, Brands AMA (2015). Does self-efficacy affect cognitive performance in persons with clinically isolated syndrome and early relapsing remitting multiple sclerosis? Multiple Sclerosis International, DOI: 10.1155/2015/960282

Oncology

Goetghebeur PJD & Wesnes KA (2018). Cognitive assessment in oncology patients reveals age-sensitive attentional impairment and deficits to a neurogenesis measure: An unmet need? Poster presentation at the ISCTM 14th Annual Scientific Meeting, February 20-22, 2018, Washington DC, USA

Kohli S, Fisher SG, Tra Y, Adams MA, Mapstone MM, Wesnes KA, Jean-Pierre P, Roscoe JA, Morrow GR (2009). The effect of modafinil on cognitive function in breast cancer Survivors. Cancer 115: 2605-2016.

McNamara P (2002). Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care. Palliative Medicine. 16: 425-434.

Walker LG, Walker MB, Heys SD, Lolley J, Wesnes KA, Eremin O (1997). The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial. Psycho-Oncology. 6: 290-301.

Walker LG, Wesnes KA, Heys SD, Walker MB, Lolley J, Eremin O (1996). The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments. European Journal of Cancer. 32A: 2275-2283.

Sleep Disorders including Excessive Daytime Sleepiness

Czeisler CA, Walsh JK, Wesnes KA, Arora S, Roth T (2009) Randomized Clinical Trial of Armodafinil for the Treatment of Excessive Sleepiness Associated With Shift-Work Disorder. Mayo Clinic Proceedings 84: 958-972.

Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S, Niebler GE, Roth T (2006). The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Current Medical Research Opinion. 22: 761-774.

Hirshkowitz M, Black JE, Wesnes KA, Niebler G, Arora S, Roth T (2007). Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respiratory Medicine. 101: 616-627.

Roth T, Rippon GA, Arora S (2008). Armodafinil improves wakefulness and long-term episodic memory in nCPAP adherent patients with excessive sleepiness associated with obstructive sleep apnea. Sleep Breath. 12: 53-62.

Roth T, White D, Schmidt-Nowara W, Wesnes KA, Niebler G, Arora S, Black J (2006). Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. *Clinical Therapeutics*. 28: 689-706.

Wesnes KA, Luthringer R, Ambrosetti L, Edgar C, Petrini O (2003). The effects of a combination of panax ginseng, vitamins and minerals on mental performance, mood and physical fatigue in nurses working night shifts: A double blind, placebo-controlled trial. *Current Topics in Nutraceutical Research*. 1: 169-174.

Wesnes KA, Walker MB, Walker LG, Heys SD, White L, Warren R, Eremin O (1997). Cognitive performance and mood after a weekend on call in a surgical unit. *The British Journal of Surgery*. 84: 493-495.

Wesnes KA, Warburton DM (1984). A comparison of temazepam and flurazepam in terms of sleep quality and residual changes in performance. *Neuropsychobiology*. 11: 255-259.

Wesnes KA, Warburton DM (1986). Effects of temazepam on sleep quality and subsequent mental efficiency under normal sleeping conditions and following delayed sleep onset. *Neuropsychobiology*. 15: 187-191.

Traumatic Brain Injury

Keith MS, Stanislav SW, Wesnes KA (1998). Validity of a cognitive computerized assessment system in braininjured patients. *Brain Injury*. 12: 1037-1043.

Lieberman JN, Stewart WF, Wesnes KA, Troncoso J (2002). Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury. *The Journal of Neurology*. 58: 1038-1044.

Ripley DL, Morey CE, Gerber D, Harrison-Felix C, Brenner L, Pretz C, Cusick C, Wesnes KA (2014). Atomoxetine for Attention Deficits Following Traumatic Brain Injury: Results from a Randomized Controlled Trial. *Brain Injury* 28: 1514-22.

Other Patient Populations

Biegstraaten M, Wesnes KA, Luzy C, Petakov M, Mrsic M, Niederau C, Giraldo P, Hughes D, Mehta A, Mengel E, Hollak CEM, Marodi L, Aerts JMRG, van Schaik IV (2012). The cognitive profile of type 1 Gaucher disease patients. *Journal of Inherited Metabolic Disease* 35: 1093-1099.

Steadman J, Pawlby S, Mayers A, Bucks R, Gregoire A, Miele-Norton M, Hogan A (2007). An exploratory study of the relationship between mother–infant interaction and maternal cognitive function in mothers with mental illness. *Journal of Reproductive and Infant Psychology*. 25(4): 255-269.

Smith MA, Else JE, Paul L, Foster JK, Walker M, Wesnes K, Riby LM. (2014). Functional living in older adults with type 2 diabetes: Executive functioning, dual task performance and the impact on postural stability and motor control. *Journal of Aging and Health* 26:841-859.

Harrison SL, Stephan BCM, Siervo M, Granic A, Davies A, Wesnes KA, Kirkwood TBL, Robinson L, Jagger C (2015). Is there an association between metabolic syndrome and cognitive function in the very old? The Newcastle 85+ study. *Journal of the American Geriatrics Society* DOI: 10.1111/jgs.13358

CLINICAL TRIALS IN VOLUNTEERS

Wesnes KA, McNamara C, Annas p (2016). Norms for healthy adults aged 18 to 87 years for the CDR System: An automated set of tests of attention, information processing and memory for use in clinical trials. *Journal of Psychopharmacology* DOI: 10.1177/0269881115625116

Clinical Trials in Paediatric and Adolescent Populations

Coley DA, Greeves R, Saxby BK (2007). The effect of low ventilation rates on the cognitive function of a primary school class. *International Journal of Ventilation* 6 (2): 107-112. Edgar C, Wesnes KA (2008). Cognition assessment in paediatric clinical trials. *Drug Discovery Today* 13: 79-85.

Ingwersen J, Defeyter MA, Kennedy DO, Wesnes KA, Scholey AB (2007). A low glycaemic index breakfast cereal preferentially prevents children's cognitive performance from declining throughout the morning. *Appetite*. 49: 240 -244.

Jóźwiak S, Veggiotti P, Moreira J, Gama H, Rocha F, Soares-da-Silva P (2018). Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures. *Epilepsy Behav.* 81:1-11. doi: 10.1016/j.yebeh.2018.01.029.

Kennedy DO, Jackson PA, Elliott JM, Scholey AB, Robertson BC, Greer J, Tiplady B, Buchanan T, Haskell CF (2009). Cognitive and mood effects of 8 weeks' supplementation with 400 mg or 1000 mg of the omega-3 essential fatty acid docosahexaenoic acid (DHA) in healthy children aged 10-12 years. *Nutritional Neuroscience*. 12: 48-56.

Lloyd A, Brett D, Wesnes K (2010). Coherence training in children with Attention-Deficit Disorder: Cognitive function and behavioral changes. *Alternative Therapies in Health and Medicine* 16: 34-42.

Maldonado EF, Fernandez FJ, Traines MV, Wesnes KA, Petrini O, Zangara A, Enguix A, Ambrosetti L (2008). Cognitive performance and morning levels of salivary cortisol and a-amylase in children reporting high vs. low daily stress perception. *The Spanish Journal of Psychology*. 11(1): 3-15.

Preece AW, Goodfellow S, Wright MG, Butler SR, Dunn EJ, Johnson Y, Manktelow TC, Wesnes KA (2005). Effect of 902 MHz mobile phone transmission on cognitive function in children. *Bioelectromagnetics*. 7: 138-143.

Taib MNM, Shariff ZM, Saad SL, Wesnes KA, Sariman S. (2011). The effect of lactose-isomaltulose on cognitive performance of young children: a double blind cross-over design study. *Appetite* 58:81-87.

Wesnes KA, Pincock C, Richardson D, Helm G, Hails S (2003). Breakfast reduces declines in attention and memory over the morning in school children. *Appetite*. 41(3): 329-331.

Wesnes KA, Pincock C, Scholey A (2012). Breakfast is associated with enhanced cognitive function in schoolchildren: An internet based study. *Appetite* 59: 646-649.

Phase I: Safety, Tolerability, Pharmacodynamic and Interaction Trials

Beuzen JN, Taylor N, Wesnes KA, Wood A (1999). A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. *Journal of Psychopharmacology*. 13: 152-158.

Dunbar G, Boeijinga PH, Demazieres A, Cisterni C, Kuchibhatla R, Wesnes KA, Luthringer R (2007). Effects of TC- 1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. *Psychopharmacology*. 191: 919-929.

Dunbar G, Kuchibhatla R (2006). Cognitive enhancement in man with Ispronicline, a nicotinic partial agonist. *Journal of Molecular Neuroscience*. 30: 169–172.

Hanks GW (1995). Morphine sans morpheus. *Lancet* 346: 652-3.

Hanks GW, O'Neill WM, Simpson PM, Wesnes KA (1995). The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects. *European Journal of Clinical Pharmacology*. 48: 455-460.

Hendriks V, van den Brink W, Blanken P, Bosman I, van Ree J (2001). Heroin self-administration by means of 'chasing the dragon': pharmacodynamics and bioavailability of inhaled heroin. *European Neuropsychopharmacology*. 11: 241-252.

Holland RL, Wesnes KA, Dietrich B (1994). Single dose human pharmacology of umespirone. *European Journal of Clinical Pharmacology*. 46: 461-468.

Kastberg H, Jansen JA, Cole G, Wesnes KA (1998). Tiagabine; Absence of kinetic or dynamic interactions with ethanol. *Drug Metabolism and Drug Interactions*. 14: 259-273.

Kay GG, Wesnes KA (2005). Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. *BJU International*. 96: 1055-1062.

Katz DA, Locke C, Liu W, Zhang J, Achari R, Wesnes KA, Tracy KA (2016). Single dose interaction study of the arginine vasopressin type 1B receptor antagonist ABT-436 and alcohol in moderate alcohol drinkers. *Alcoholism: Clinical and Experimental Research in press*

Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, Burnett AL (2003). Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. *Neuropsychopharmacology*. 28: 542-551.

Kleinbloesem CH, Jaquet-Muller F, al-Hamdan Y, Baldauf C, Gisclon L, Wesnes K, Curtin CR, Stubbs RJ, Walker SA, Brunner-Ferber F (1996). Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men. *Clinical Pharmacology and Therapeutics*. 59: 675-685.

Legangneux E, McEwen J, Wesnes KA, Bergougnan L, Miget N, Canal M, L'Heritier C, Pinquier JL, Rosenzweig P (2000). The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. *Journal of Psychopharmacology*. 14: 164-171.

Lipton RB, Kolodner K, Wesnes KA (2005). Assessment of cognitive function of the elderly population: effects of darifenacin. *The Journal of Urology*. 173: 493-498.

Mason BJ, Goodman AM, Dixon RM, Hameed MH, Hulot T, Wesnes KA, Hunter JA, Boyeson MG (2002). A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. *Neuropsychopharmacology*. 27: 596-606.

Modi NB, Dresser M, Desai D, Edgar C, Wesnes KA (2007). Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. *Journal of Clinical Pharmacology*. 47: 315-322.

Morain P, Lestage P, De Nanteuil G, Jochemsen R, Robin J-L, Guez D, Boyer P-A (2002). S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. *CNS Drug Reviews*. 8: 31-52.

Morain P, Robin L, Nanteuil G De, Jochemsen R, Heidet V (2000). Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study. *British Journal of Clinical Pharmacology*. 50:350-359.

Nathan PJ et al. (2012) Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the mu-opioid receptor inverse agonist GSK1521498. *Journal of Clinical Pharmacology* 52: 1456-1467.

Neave N, Reid C, Scholey AB, Thompson JM, Moss M, Ayre G, Wesnes KA, Girdler NM (2000). Dose-dependent effects of flumazenil on cognition, mood, and cardio-respiratory physiology in healthy volunteers. *British Dental Journal*. 189: 668-674.

O'Neill WM, Hanks GW, Simpson PM, Fallon MT, Jenkins E, Wesnes KA (2000). The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. *Pain*. 85: 209-215.

O'Neill WM, Hanks GW, White L, Simpson PM, Wesnes KA (1995). The cognitive and psychomotor effects of opioid analgesics. I. A randomised controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects. *European Journal of Clinical Pharmacology*. 48: 447-453.

Otmani S, Demazieres A, Staner C, Jacob N, Nir T, Zisapel N, Staner L (2008). Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. *Human Psychopharmacology* 23: 693-705.

Palmer C, Ellis K, O'Neil B, Croft R, Leung C, Oliver C, Wesnes KA, Nathan P (2007). The cognitive effects of modulating the glycine site of the NMDA receptor with high-dose glycine in healthy controls. *Human Psychopharmacology*. 23: 151-159.

Parrott AC, Wesnes KA (1987). Promethazine, scopolamine and cinnarizine: comparative time course of psychological performance effects. *Psychopharmacology*. 92: 513-519.

Pomara N, Willoughby L, Wesnes KA, Greenblatt DJ, Sidtis JJ (2005). Apolipoprotein E epsilon4 allele and lorazepam effects on memory in high-functioning older adults. *Archives of General Psychiatry*. 62: 209- 216.

Pomara N, Willoughby LM, Hashim A, Sershen H, Sidtis JJ, Wesnes KA, Greenblatt DJ, Lajtha A (2004). Effects of acute lorazepam administration on aminergic activity in normal elderly subjects: relationship to performance effects and apolipoprotein genotype. *Neurochemical Research*. 29: 1391-1398.

Pomara N, Willoughby LM, Sidtis JJ, Doraiswamy PM, Wesnes KA, Cooper TB, Greenblatt DJ (2004). Baseline plasma GABA: its relationship to the adverse effects of acute lorazepam administration on cognition in the elderly. *Neurochemical Research*. 29: 2311-2315.

Pomara N, Willoughby LM, Wesnes KA, Sidtis JJ (2004). Increased anticholinergic challenge-induced memory impairment associated with the APOE-epsilon4 allele in the elderly: a controlled pilot study. *Neuropsychopharmacology*. 29: 403-409.

Rapeport WG, Muirhead DC, Williams SA, Cross M, Wesnes KA (1996). Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. *Journal of Clinical Psychiatry*. 57: 24-28.

Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes KA (1996). Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. *Journal of Clinical Psychiatry*. 57: 20-23.

Ruwe FJL, Smulders RA, Kleijn HJ, Hartmans HLA, Sitsen JMA (2001). Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects. *Human Psychopharmacology - Clinical and Experimental*. 16: 449-459.

Sitsen J, Maris F, Timmer C (2001). Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. *Eur J Drug Metab Pharmacokinet* 26: 109-121.

Shah J, Wesnes KA, Kovelesky RA, Henney HR (2006). Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. *Clinical Therapeutics*. 28:1308-1317.

Sitsen JMA, Maris FA, Timmer CJ (2001). Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. *European Journal of Drug Metabolism and Pharmacokinetics*. 26: 109-121.

Sitsen JMA, Voortman G, Timmer CJ (2000). Pharmacokinetics of mirtazapine and lithium in healthy male subjects. *Journal of Psychopharmacology*. 14: 172-176.

van Harten J, Stevens LA, Raghoobar M, Holland RL, Wesnes KA, Cournot A (1992). Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. *Clinical Pharmacology and Therapeutics*. 5: 427-435.

Wesnes KA, Annas P, Edgar CJ, Deeprase C, Karlsten R, Philipp A, Kalliomäki J, Segerdahl M (2010). Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers. *Journal of Psychopharmacology* 24: 1659-1669.

Wesnes KA, Edgar C, Tretter R, Bolodeoku J (2009). Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. *Expert Opinion on Drug Safety* 8: 1-12.

Wesnes KA, Garratt C, Wickens M, Gudgeon A, Oliver S (2000). Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. *British Journal of Clinical Pharmacology*. 49: 110-117.

Wesnes KA, Simpson PM, Christmas L, McClelland GR, Joiner IM (1989). Acute cognitive effects of moclobemide and trazodone, alone and in combination with alcohol, in the elderly. *British Journal of Clinical Pharmacology*. 27: 647-648.

Wesnes KA, Simpson PM, Jansson B, Grahnen A, Weimann HJ, Kupperts H (1997). Moxonidine and cognitive function: interactions with moclobemide and lorazepam. *European Journal of Clinical Pharmacology*. 52: 351-358.

Williams SA, Wesnes KA, Oliver SD, Rapeport WG (1996). Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol. *Journal of Clinical Psychiatry*. 57: 7-11.

Phase I: Scopolamine Model of Dementia

Anand R, Wesnes KA (1990). Cognition-enhancing effects of moclobemide, a reversible MAO inhibitor, in humans. *Advances in neurology*. 51: 261-268.

Barker A, Jones R, Prior J, Wesnes KA (1998). Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers: A 6-year follow-up. *International Journal of Geriatric Psychiatry*. 13: 244-247.

Barker A, Jones R, Simpson PM, Wesnes KA (1995). Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers. *International Journal of Geriatric Psychiatry*. 10: 1059-1062.

Ebert U, Oertel R, Wesnes KA, Kirch W (1998). Effects of physostigmine on scopolamine-induced changes in quantitative electroencephalogram and cognitive performance. *Human Psychopharmacology*. 13: 199-210.

Ebert U, Siepmann M, Oertel R, Wesnes KA, Kirch W (1998). Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. *Journal of Clinical Pharmacology*. 38: 720-726.

Ellis JR, Ellis KA, Bartholomeusz CF, Harrison BJ, Wesnes KA, Erskine FF, Vitetta L, Nathan PJ (2005). Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. *International Journal of Neuropsychopharmacology*. 8: 1-15.

Jones RW, Wesnes KA, Kirby J (1991). Effects of NMDA modulation in scopolamine dementia. *Annals of New York Academy of Sciences*. 640: 241-244.

Lenz RA, Baker JD, Locke C, Rueter LE, Mohler EG, Wesnes KA, Abi-Saab W, Saltarelli MD. (2012). The Scopolamine Model as a Pharmacodynamic Marker in Early Drug Development: A New Paradigm? *Psychopharmacology* 220: 799-807.

Wesnes KA (1994). De l'utilité d'un modèle adéquat dans les essais médicamenteux à propos de la maladie d'Alzheimer. *Patient Care*. 17: 95-104.

Wesnes KA, Anand R, Lorscheid T (1990). Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia. *ACTA Psychiatrica Scandinavica Supplementum*. 360: 71-72.

Wesnes KA, Anand R, Simpson PM, Christmas L (1990). The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. *Journal of Psychopharmacology* 4: 219-232.

Wesnes KA, Jones RW, Kirby J (1991). The effects of D-cycloserine, a glycine agonist, in a human model of the cognitive deficits associated with ageing and dementia. *British Journal of Clinical Pharmacology*. 31: 577- 578.

Wesnes KA, Revell A (1984). The separate and combined effects of scopolamine and nicotine on human information processing. *Psychopharmacology*. 84: 5-11.

Wesnes KA, Simpson PM (1988). Can scopolamine produce a model of the memory deficits seen in ageing and dementia? . *Practical Aspects of Memory: Current Research and Issues*. M. M. Gruneberg, P. E. Morris and R. N. Sykes. Chichester, Wiley. 2: 236-242.

Wesnes KA, Simpson PM, Christmas L, Anand R, McClelland GR (1989). The effects of moclobemide on cognition. *Journal of Neural Transmission*. 28: 91-102.

Wesnes KA, Simpson PM, Kidd A (1987). The use of a scopolamine model to study the nootropic effects of tenilsetam (Cas-997) in man. *Medical Science Research-Biochemistry*. 15: 1063-1064.

Wesnes KA, Simpson PM, Kidd AG (1988). An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg s.c. *Human Psychopharmacology*. 3: 27-41.

Wesnes KA, Simpson PM, White L, Pinker S, Jertz G, Murphy M, Siegfried K (1991). Cholinesterase inhibition in the scopolamine model of dementia. *Annals of the New York Academy of Sciences*. 640: 268-271.

Zangara A (2003). Huperzine A: An alkaloid with nootropic and neuroprotective properties. *Current Topics in Nutraceutical Research*. 1: 193-204.

Zangara A (2003). The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. *Pharmacology, Biochemistry and Behaviour*. 75: 675-686.

Clinical Trials with Nutrients & Natural Products/Substances

Camfield DA, Scholey A, Pipingas A, Silberstein R, Kras M, Nolidin K, Wesnes K, Pace M, Stough C (2012). Steady state visually evoked potential (SSVEP) topography changes associated with cocoa flavanol consumption. *Physiology & Behavior* 105: 948-957.

Ellis KA, Stough C, Vitetta L, Heinrich K, Nathan PJ (2001). An investigation into the acute nootropic effects of hypericum perforatum L. (St John's Wort) in healthy human volunteers. *Behavioural Pharmacology*. 12:173-182.

Ford CE, Scholey AB, Ayre G, Wesnes KA (2002). The effect of glucose administration and the emotional content of words on heart rate and memory. *Journal of Psychopharmacology*. 16: 241-244.

Goetghebeur PJD & Wesnes KA (2018). Evaluation of the Cognition Enhancement Potential of Nutraceuticals and Natural Products Using the CDR System. Presented at the 4th International Congress on Advances in Natural Medicines, Nutraceuticals & Neurocognition, London, UK, July 19-20, 2018.

Harrison BJ, Oliver JS, Norman TR, Burrows GD, Wesnes KA, Nathan PJ (2004). Selective effects of acute serotonin and catecholamine depletion on memory in healthy women. *Journal of Psychopharmacology*. 18: 32-40.

Haskell CF, Kennedy D, Milne AL, Wesnes KA, Scholey AB (2008). The effects of L-theanine, caffeine and their combination on cognition and mood. *Biological Psychology*. 77: 113-122.

Haskell CF, Kennedy DO, Wesnes KA, Milne AL, Scholey AB (2007). A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guarana in humans. *Journal of Psychopharmacology*. 21: 65-70.

Haskell CF, Kennedy DO, Wesnes KA, Scholey AB (2005). Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. *Psychopharmacology*. 179: 813-825.

Ingwersen J, Defeyter MA, Kennedy DO, Wesnes KA, Scholey AB (2007). A low glycaemic index breakfast cereal preferentially prevents children's cognitive performance from declining throughout the morning. *Appetite*. 49: 240 -244.

Isaacs E, Oates J (2008). Nutrition and cognition: assessing cognitive abilities in children and young people. *European Journal of Nutrition*. 47(3): 4-24

Jones EK, Sünram-Lea SI, Wesnes KA. (2012). Acute ingestion of different macronutrients differentially enhances aspects of memory and attention in healthy young adults. *Biological Psychology* 89: 477-468.

Kennedy D, Haskell CF, Mauri P, Scholey AB (2007). Acute cognitive effects of standardised Ginkgo Biloba extract complexed with phosphatidylserine. *Human Psychopharmacology*. 22: 199–210.

Kennedy D, Jackson P, Haskell CF, Scholey AB (2007). Modulation of cognitive performance following single doses of 120 mg Ginkgo biloba extract administered to healthy young volunteers. *Human Psychopharmacology*. 22: 559-566.

Kennedy DO, Haskell CF, Wesnes KA, Scholey AB (2004). Improved cognitive performance in human volunteers following administration of guarana (*Paullinia cupana*) extract: comparison and interaction with *Panax ginseng*. *Pharmacology, Biochemistry and Behaviour*. 79: 401-411.

Kennedy DO, Jackson PA, Elliott JM, Scholey AB, Robertson BC, Greer J, Tiplady B, Buchanan T, Haskell CF (2009).

Cognitive and mood effects of 8 weeks' supplementation with 400 mg or 1000 mg of the omega-3 essential fatty acid docosahexaenoic acid (DHA) in healthy children aged 10-12 years. *Nutritional Neuroscience*. 12: 48-56.

Kennedy DO, Raey JL, Scholey AB (2007). Effects of 8 weeks administration of Korean *Panax ginseng* extract on the mood and cognitive performance of healthy individuals. *Journal of Ginseng Research*. 31: 34-43.

Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA (2002). Modulation of mood and cognitive performance following acute administration of *Melissa officinalis* (lemon balm). *Pharmacology, Biochemistry and Behaviour*. 72: 953-964.

Kennedy DO, Scholey AB, Wesnes KA (2000). The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. *Psychopharmacology*. 151: 416-423.

Kennedy DO, Scholey AB, Wesnes KA (2001). Differential, dose dependent changes in cognitive performance following acute administration of a Ginkgo biloba/*Panax ginseng* combination to healthy young volunteers. *Nutritional Neuroscience*. 4: 399-412.

Kennedy DO, Scholey AB, Wesnes KA (2001). Dose dependent changes in cognitive performance and mood following acute administration of Ginseng to healthy young volunteers. *Nutritional Neuroscience*. 4: 295- 310.

Kennedy DO, Scholey AB, Wesnes KA (2002). Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults. *Physiology & Behaviour*. 75: 739-751.

Kennedy DO, Wake G, Savelev S, Tildesley NT, Perry EK, Wesnes KA, Scholey AB (2003). Modulation of mood and cognitive performance following acute administration of single doses of melissa officinalis (lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. *Neuropsychopharmacology*. 28: 1871-1881.

Mace J, Porter R, Dalrymple-Alford J, Wesnes KA, Anderson T (2011). The effects of acute tryptophan depletion on neuropsychological function, mood and movement in the healthy elderly. *Journal of Psychopharmacology* 25: 1337-1343.

Maher BF, Stough C, Shelmerdine A, Wesnes KA, Nathan PJ (2002). The acute effects of combined administration of Ginkgo biloba and Bacopa monniera on cognitive function in humans. *Human Psychopharmacology*. 17: 163-164.

Matrenza C, Hughes JM, Kemp AH, Wesnes KA, Harrison BJ, Nathan PJ (2004). Simultaneous depletion of serotonin and catecholamines impairs sustained attention in healthy female subjects without affecting learning and memory. *Journal of Psychopharmacology*. 18: 21-31.

Moss L, Rouse M, Wesnes KA, Moss M (2010). Differential Effects of the Aromas of Salvia Species on Memory and Mood. *Human Psychopharmacology: Clinical and Experimental* 25: 388-396.

Moss M, Cook J, Wesnes KA, Duckett P (2003). Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults. *International Journal of Neuroscience*. 113: 15-38.

Moss M, Hewitt S, Moss L, Wesnes KA (2008). Modulation of cognitive performance and mood by aromas of peppermint and ylang-ylang *The International Journal of Neuroscience*. 118: 59-77.

Moss M, Howarth R, Wilkinson L, Wesnes KA (2006). Expectancy and the aroma of roman chamomile influence mood and cognition in healthy volunteers. *International Journal of Aromatherapy*. 16: 63-73.

Moss MC, Scholey AB, Wesnes KA (1998). Oxygen administration selectively enhances cognitive performance in healthy young adults: a placebo-controlled double-blind crossover study. *Psychopharmacology*. 138: 27- 33.

Nathan PJ, Ricketts E, Wesnes KA, Mrazek L, Greville W, Stough C (2002). The acute nootropic effects of Ginkgo biloba in healthy older human subjects: a preliminary investigation. *Human Psychopharmacology*. 17: 45-49. 281.

Ossoukhova A, Owen L, Savage K, Meyer M, Ibarra A, Roller M, Pipingas A, Wesnes K, Scholey A (2015). Improved working memory performance following administration of a single dose of American ginseng (*Panax quinquefolius* L.) to healthy middle-age adults. *Human Psychopharmacology Clinical Experimental* 30: 108–122.

Pase M, Scholey A, Pipingas Andrew, Kras M, Nolidin K, Gibbs A, Wesnes K, Stough C. (2013). Cocoa polyphenols enhance positive mood states but not cognitive performance: a randomized, placebo-controlled trial. *Journal of Psychopharmacology* 27: 451-458.

Pengelly A, Snow J, Mills SY, Scholey A, Wesnes K, Butler LR. (2012). Short-Term Study on the Effects of Rosemary on Cognitive Function in an Elderly Population. *Journal of Medicinal Food* 15: 10-17.

Perry NSL, Menzies R, Hodgson F, Wedgewood P, Howes MR, Brooker HJ, Wesnes KA, Perry EK (2018). A randomised double-blind placebo-controlled pilot trial of a combined extract of sage, rosemary and melissa, traditional herbal medicines, on the enhancement of memory in normal healthy subjects, including influence of age. *Phytomedicine*. 39: 42-48. doi: 10.1016/j.phymed.2017.08.015. yan J, Croft K, Mori T, Wesnes KA, Spong J, Downey LA, Kure C, Lloyd J, Stough C (2008). An examination of the effects of the antioxidant Pycnogenol on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. *Journal of Psychopharmacology*. 22: 553-562.

Scholey A, Tildesley NT, Ballard CG, Wesnes KA, Tasker A, Perry EK, Kennedy DO (2008). An extract of *Salvia* (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. *Psychopharmacology* 198: 127-139.

Scholey AB, Kennedy D, Wesnes KA (2005). The psychopharmacology of herbal extracts: issues and challenges. *Psychopharmacology*. 179: 705-707.

Scholey AB, Kennedy DO (2004). Cognitive and physiological effects of an "energy drink": an evaluation of the whole drink and of glucose, caffeine and herbal flavouring fractions. *Psychopharmacology*. 176: 320- 330.

Scholey AB, Moss MC, Neave N, Wesnes KA (1999). Cognitive performance, hyperoxia, and heart rate following oxygen administration in healthy young adults. *Physiology and Behaviour*. 67: 783-789.

Scholey AB, Moss MC, Wesnes KA (1998). Oxygen and cognitive performance: the temporal relationship between hyperoxia and enhanced memory. *Psychopharmacology*. 140: 123-126.

Stough C, Downey L, Sibling B, Lloyd J, Kure C, Wesnes K, Camfield D. (2012). The effects of 90-day supplementation with the Omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population. *Neurobiology of Aging* 33:824.e1-3.

Stough C, Downey LA, Lloyd J, Silber B, Redman S, Hutchison C, Wesnes KA, Pradeep NJ (2008). Examining the nootropic effects of a special extract of *Bacopa monniera* on human cognitive functioning: 90 day double blind placebo-controlled randomized trial. *Phytotherapy Research*. 22: 1629-1634.

Stough C, Kure C, Tarasuik J, Lloyd J, Downey L, Scholey A, Wesnes A (2009). A Randomized, Double-blind, Placebo Controlled Study Examining the Effects of a Combination Nutraceutical Formula on Cognitive Functioning and Mood. *Journal of the American Nutraceutical Association* 12: 12-19.

Stough C, Pase MP, Cropley V, Myers K, Nolidin R, Camfield D, Wesnes K, Pipingas A, Croft K, Chang D, Scholey AB (2012). A randomized controlled trial investigating the effect of Pycnogenol and CDRI08 herbal medicines on cognitive, cardiovascular, and biochemical functioning in cognitively healthy elderly people: the Australian Research Council Longevity Intervention (ARCLI) study protocol (ACTRN12611000487910). *Nutrition Journal* 11:11 doi:10.1186/1475-2891-11-11

Stough C, Scholey A, Cropley V, Wesnes K, Zangara A, Pase M, Savage K, Downey LA (2013). Examining the cognitive effects of a special extract of *Bacopa monniera* (CDRI08: Keenmnd): A review of ten years of research at Swinburne University. *Journal of Pharmacy & Pharmaceutical Sciences* 11:11. doi:10.1186/1475-2891-11-11

Súnram-Lea SI, Birchall RJ, Wesnes KA, Petrini O (2004). The effect of acute administration of 400MG of *Panax Ginseng* on cognitive performance and mood in healthy young volunteers. *Current topics in Nutraceutical Research*. 3: 251-254.

Taib MNM, Shariff ZM, Saad SL, Wesnes KA, Sariman S. (2011). The effect of lactose-isomaltulose on cognitive performance of young children: a double blind cross-over design study. *Appetite* 58: 81-87.

Tildesley NT, Kennedy DO, Perry EK, Ballard CG, Savelev S, Wesnes KA, Scholey AB (2003). *Salvia lavandulaefolia* (Spanish sage) enhances memory in healthy young volunteers. *Pharmacology, Biochemistry and Behaviour*. 75: 669-674.

Tildesley NT, Kennedy DO, Perry EK, Ballard CG, Wesnes KA, Scholey AB (2005). Positive modulation of mood and cognitive performance following administration of acute doses of *Salvia lavandulaefolia* essential oil to healthy young volunteers. *Physiology & Behaviour*. 83: 699-709.

Wesnes KA (2010). Cognition Enhancement – Expanding Opportunities in Drug Development. *International Clinical Trials* June 2010: 66-72.

Wesnes KA (2013) Natural substances as treatments for age-related cognitive declines. In: *Advances in Natural Medicines, Nutraceuticals and Neurocognition*. In C. Stough & A. Scholey (Eds), CRC Press, Taylor & Francis, Boca Raton. ISBN 9781439893609.

Wesnes KA, Zangara A (2004). Natural products as cognition enhancing agents. *Cognition Enhancing Drugs*. J. J. Buccafusco. Basel, Birkhauser Verlag: 151– 178.

Wesnes KA, Barrett M, Udani J. (2013) An evaluation of the cognitive and mood effects of an energy shot over a 6 hour period in volunteers: A randomized, double-blind, placebo controlled, cross-over study. *Appetite* DOI: 10.1016/j.appet.2013.04.005

Wesnes KA, Faleni RA, Hefting NR, Hoogsteen G, Houben JJ, Jenkins E, Jonkman JH, Leonard J, Petrini O, van Lier JJ (1997). The cognitive, subjective, and physical effects of a ginkgo biloba/panax ginseng combination in healthy volunteers with neurasthenic complaints. *Psychopharmacology Bulletin*. 33: 677-683.

Wesnes KA, Pincock C, Richardson D, Helm G, Hails S (2003). Breakfast reduces declines in attention and memory over the morning in school children. *Appetite*. 41: 329-331.

Wesnes KA, Warburton DM (1983). Effects of scopolamine on stimulus sensitivity and response bias in a visual vigilance task. *Neuropsychobiology*. 9: 154-157.

Wesnes KA, Ward T, McGinty A, Petrini O (2000). The memory enhancing effects of a ginkgo biloba/panax ginseng combination in healthy middle-aged volunteers. *Psychopharmacology*. 152: 353-361.

Wilkinson L, Scholey AB, Wesnes KA (2002). Chewing gum selectively improves aspects of memory in healthy volunteers *Appetite* 38: 235-236.

Zangara A, Wesnes KA (2013) Herbal cognitive enhancers: New developments and challenges for therapeutic applications. In: M.K.Thakur & I.S. Suresh (Eds). *Brain Aging and Therapeutic Interventions*, Springer. ISBN 978-94-007-5237-5. pp 267-289.

Clinical Trials with Nicotine

Edwards JA, Wesnes KA, Warburton DM, Gale A (1985). Evidence of more rapid stimulus evaluation following cigarette smoking. *Journal of Allergy and Clinical Immunology*. 10: 113-126.

Parrott A, Winder G (1989). Nicotine chewing gum and cigarette smoking: comparative effects upon vigilance and heart rate. *Psychopharmacology*. 97: 257-261.

Parrott AC, Garnham NJ, Wesnes KA, Pincock C (1996). Cigarette smoking and abstinence: Comparative effects upon cognitive task performance and mood state over 24 hours. *Human Psychopharmacology-Clinical and Experimental*. 11: 391-400.

Wesnes KA (1987). Nicotine Increases mental efficiency, But how? Tobacco Smoke and Nicotine: A Neurobiological Approach. W. R. Martin, G. R. Van Loon, E. T. Iwamoto and D. L. Davis. New York, Plenum: 63-81. 267.

Wesnes KA, Edgar C, Kezic I, Salih H, de Boer P (2013) Effects of nicotine withdrawal on cognition in a clinical trial setting. *Psychopharmacology* 229: 133-140.

Wesnes KA, Parrott A (1992). Smoking, nicotine and human performance. *Handbook of Human Performance*. A. Smith and D. Jones. London, Academic Press. 2: 127-167.

Wesnes KA, Revell A (1984). The separate and combined effects of scopolamine and nicotine on human information processing. *Psychopharmacology*. 84: 5-11.

Wesnes KA, Simmons D, Rook M, Simpson PM (1987). A double blind placebo controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly. *Human Psychopharmacology*. 2: 159-169.

Wesnes KA, Simpson PM (1988). Puff by puff profiles of performance, mood and acceptability in low and non-low tar smokers. *The Pharmacology of Nicotine*. M. J. Rand and K. Thurau. Oxford, IRL Press: 406-408.

Wesnes KA, Warburton DM (1983). Effects of smoking on rapid information processing performance. *Neuropsychobiology*. 9: 223-229.

Wesnes KA, Warburton DM (1983). Smoking, nicotine and human performance. *Pharmacology & Therapeutics*. 21: 189-208.

Wesnes KA, Warburton DM (1984). Effects of scopolamine and nicotine on human rapid information processing performance. *Psychopharmacology*. 82: 147-150.

Wesnes KA, Warburton DM (1984). The effects of cigarettes of varying yield on rapid information processing performance. *Psychopharmacology*. 82: 338-342.

Wesnes KA, Warburton DM, Matz B (1983). Effects of nicotine on stimulus sensitivity and response bias in a visual vigilance task. *Neuropsychobiology*. 9: 41-44.

Clinical Trial Methodology & Reviews

Brooker H, Meinel N (2008). Brain Power: Translational medicine. *European Pharmaceutical Contractor*. 32-36

Byrom B, Mundt J (2005). The value of computer-administered self-report data in central nervous system clinical trials. *Current Opinion in Drug Discovery and Development* 89: 374-383.

Cusack M (2008). Cerebral Intelligence. *European Pharmaceutical Contractor*. Spring, 48-51.

Ellis KA, Mehta MA, Wesnes KA, Armstrong S, Nathan PJ (2005). Combined D1/D2 receptor stimulation under conditions of dopamine depletion impairs spatial working memory performance in humans. *Journal of Psychopharmacology*. 181: 771-780.

Hall ST, Puech A, Schaffler K, Wesnes KA, Gamzu ER (1990). Early clinical testing of cognition enhancers: prediction of efficacy. *Journal of Pharmacopsychiatry*. 23: 57-58.

Harrison JE, Wesnes KA (2006). Objective cognitive testing and patient-reported accounts of cognitive function. *Patient Reported Outcomes*. 36: 5-8.

Horton RJ, Minniti A, Mireylees S, McEntegart D (2008). A randomized trial to determine the impact on compliance of a psychophysical peripheral cue based on the Elaboration Likelihood Model. *Contemporary Clinical Trials*. 29: 823-828

Meinel N, Satek S, Edgar C, Wesnes KA (2007). *Translational Medicine. ICT Clinical Trial Management*. 12-18

Mundt JC, Geraltz DS, Moore HK (2006). Dial "T" for testing: Technological flexibility in neuropsychological assessment. *Telemedicine journal and e-health: the official journal of the American Telemedicine Association*. 12(3): 317-323

Papp KV, Walsh SJ, Snyder PJ (2009) Immediate and delayed effects of cognitive interventions in healthy elderly: A review of current literature and future directions. *Alzheimer's and Dementia*. 5: 56-60

Prasad C, Packer L, Benzie IFF, Hamazaki T, Riedel WJ, Wesnes KA (2003) *Nutraceutical Research & Education Now: We can't afford to wait*. *Current Topics in Nutraceutical Research* 1: vii.

Wesnes KA (2000). The value of assessing cognitive function in drug development. *Dialogues in Clinical Neuroscience*. 2. 183-202.

Wesnes KA (2001). Latest developments in cognitive function assessment in drug development. *GOR* 3: 140-144.

Wesnes KA (2001). The assessment of cognitive function in clinical trials. *Good Clinical Practice Journal*. 8: 10-14.

Wesnes KA (2001). The use of cognitive tests to facilitate drug and dose selection Phase I and to optimise dosing in Phase IV. *International Congress Series 1220*. 35-50.

Wesnes KA (2002). Assessing cognitive function in clinical trials: latest developments and future directions. *Drug Discovery Today*. 7(1): 29-35.

Wesnes KA (2005). An automated system for assessing cognitive function in any environment. *Proceedings of SPIE*. 5797: 24-41.

Wesnes KA (2006). Cognitive function testing: the case for standardisation and automation. *Journal of the British Menopause Society*. 12: 158-163.

Wesnes KA (2010). An evaluation of techniques to identify beneficial effects of nutrition and natural products on cognitive function. *Nutrition Reviews* 68 (Suppl. 1): S22–S28.

Wesnes KA (2010). The opportunities for treating the cognitive declines which accompany normal ageing. *Journal for Clinical Studies* May 2010: 36-42.

Wesnes KA (2010). Wake-Up to the MATRICS: Cognition Enhancement – Expanding Opportunities in Drug Development. *International Clinical Trials* June 2010: 66-72.

Wesnes KA (2013) Natural substances as treatments for age-related cognitive declines. In: *Advances in Natural Medicines, Nutraceuticals and Neurocognition*. In C. Stough & A. Scholey (Eds), CRC Press, Taylor & Francis, Boca Raton. ISBN 9781439893609.

Wesnes KA, Brooker H (2010). Pharmacodynamic Evaluation: CNS. In HG Vogel, J Maas, A Gebauer (eds.) *Drug Discovery and Evaluation: Methods in Clinical Pharmacology*, Springer Verlag Berlin, ISBN: 978-3-540-89890-0.

Wesnes KA, Edgar C (2002). Latest developments in the assessment of human cognitive function in clinical trials. *European Pharmaceutical Contractor*. 74-83.

Wesnes KA, Pincock C (2002). Practice effects on cognitive tasks: a major problem? *Lancet Neurology*. 1: 8 - 473.

Wesnes KA, Simpson PM, Christmas L (1987). The assessment of human information processing abilities in psychopharmacology. *Human Psychopharmacology: Measures and Methods*. 79-92.

Wesnes, K. A. (2003). The Cognitive Drug Research computerised assessment system: Application to clinical trials. *Memory: Basic Concepts, Disorders and Treatment*. P. De Deyn, E. Thiery and R. D'Hooge. Uitgeverij Acco, Leuven: 453–472.

Woodruff-Pak DS, Jaeger ME, Gorman C, Wesnes KA (1999). Relationships among age, conditioned stimulus unconditioned stimulus interval, and neuropsychological test performance. *Neuropsychology*. 13: 90- 102.

Zangara A, Wesnes KA (2013). Herbal cognitive enhancers: New developments and challenges for therapeutic applications. In: M.K.Thakur & I.S. Suresh (Eds). *Brain Aging and Therapeutic Interventions*, Springer. ISBN 978-94-007-5237-5. pp 267-289.

de Jager CA, Dye L, de Bruin EA, Butler L, Fletcher J, Lamport D, Latulippe ME, Spencer JPE, Wesnes KA. (2014). Markers of cognitive function: Criteria for validation and considerations for investigating the effects of foods and nutrients. *Nutrition Reviews* 72: 162-179.

Goldberg TE, Harvey PD, Wesnes KA, Snyder PJ, Schneider LS (2015). Practice Effects Due to Serial Cognitive Assessment: Implications for Preclinical Alzheimer's Disease Randomized Controlled Trials. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* 1: 103–111.

Micaletto M, Goetghebeur PJD, Wesnes KA (2019). Improving data quality and administration of CDR System in clinical trials. Presented at ISCTM 2019 Autumn Conference, Copenhagen, Denmark, 5-7 September 2019.